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ABSTRACT 
Recruitment and retention of participants in HIV vaccine trials has been challenging 
compared to other studies conducted by the Programme at Mbeya Medical Research 
Centre. The purpose of this study was to gain a deep understanding of the experiences 
and challenges faced by volunteers who participated in a HIV vaccine trial in the town of 
Mbeya in 2006 - 2007. There have been many misconceptions regarding HIV vaccine 
trials. Some of the concerns to participants were safety of the vaccine, fear of becoming 
infected by the vaccine and the amount of blood drawn for laboratory tests. 
A qualitative descriptive study approach was used to gather the required information. The 
sample for this study was drawn from an existing group of volunteers who participated in 
the vaccine trial at Mbeya Medical Research Centre in 2006-2007. A purposive sampling 
method was used to select respondents because they had had experience of being 
participants in a HIV vaccine trial. Twenty audio recorded in-depth interviews were 
conducted. The interviews were conducted at the clinic during their routine follow up 
visits. An open ended interview guideline was used to guide the discussion to elicit the 
required information from the respondents. The data was transcribed, translated and then 
analyzed by both content and thematic approach. Ethical procedures were observed, 
including getting permission from the local ethical committee in Mbeya region and 
participants were given an informed consent form to read and sign before starting the 
interview. 
Based on findings from the study, it was noted that most of people who participated in 
the vaccine trial had participated in other cohort studies which were previously conducted 
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at the research centre. It was found that respondents felt that participation in the trial 
would be their contribution to the global effort in fighting against HIV. They also felt that 
should the vaccine be successful it would a benefit to many people in future. 
It was noted that long waiting time at the clinic, blood draw and the vaccine induced 
postivity were among of the frequently mentioned concern regarding clinic procedures. 
On the other hand it was revealed that some of the respondents had nasty experiences at 
home due to rumors and misconceptions which were circulating in the community 
regarding the vaccine on trial. It was reported that the vaccine induced positivity was 
directly related to being injected with a real HIV virus. The vaccine did not cause any 
serious side effects to the participants apart from mild fevers, headaches and a pain at the 
site of injection. Respondents appreciated the close monitoring of study participants and 
the health care provided by the staff when they fell sick. 
 The information gained from the study will assist the research team to improve the 
educational seminar package for volunteers during participant recruitment in future trials 
based on the areas of concerns reported by participants of the HVT. There is the need for 
the research team to provide more information and clarification of unfamiliar terms 
(randomization, placebo and vaccine induced positivity) during educational seminars. 
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CHAPTER ONE: INTRODUCTION  
1.1 HIV/AIDS  
HIV/AIDS remains the main public health problem worldwide due to its large impact in 
people’s lives (WHO, 2006). Since the discovery of the disease in the 1980’s HIV/AIDS 
has claimed more than 25 million people’s lives globally and is responsible for marked 
demographic changes among heavily affected countries (UNAIDS, 2008). In heavily 
affected countries especially in the sub Saharan African (SSA), the disease has reduced 
life expectancy by more than 20 years (UNAIDS, 2008). The disease has slowed 
economic growth and development and thus increasing poverty in these countries (WHO, 
2006). In 2007 it was estimated that there were 33 million people living with HIV 
worldwide and 67% of them were from the sub-Saharan African countries (UNAIDS, 
2008). The epidemic caused between 1.8 to 2.3 million deaths in 2007 worldwide with 
75% of the deaths occurring in SSA countries (UNAIDS, 2008). Despite all international 
efforts and campaigns to reduce the HIV epidemic for example HIV/AIDS education, 
behavioral change education programs on abstinence, faithfulness and use of condom the 
epidemic’s future is still uncertain (WHO-UNAIDS, 2002).   
 
HIV Vaccine 
A vaccine is a substance introduced to the body to create resistance or immunity against 
disease or infection (Cichocki, 2006). A vaccine is one of the most cost effective health 
interventions when compared to treatment. Sub Saharan African countries need a HIV 
vaccine urgently because the impact of HIV /AIDS is huge (UNAIDS 2008). Currently 
there are no HIV vaccines approved for use, considerable research and clinical trials are 
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necessary before a vaccine is approved (Cichocki, 2006). However recently there has 
been news of a promising HIV vaccine from the trial conducted in Thailand to 16,000 
volunteers from 2003 to 2009. The trial found that the vaccine was safe and modest 
effective in preventing HIV by 31.2%  although there is still some work to be done for 
the vaccine to be approved (Relly, 2009).  In order to accelerate the development of HIV 
vaccine Esparza and Bhamarapravati (2000) pointed out that it was important to address 
the challenges experienced during the process of developing an effective vaccine and 
then to find solutions to them so as to increase the acceptability of the vaccine in future.  
 
Mbeya Medical Research Programme 
Mbeya Medical Research Programme (MMRP) is a nonprofit organization dealing with 
research activities on HIV/AIDS, Tuberculosis and malaria since 2000. The research 
programme also referred to as the research centre has been conducting HIV cohort 
studies in high-risk population as well as general population with valuable findings about 
HIV prevalence and incidences to the Tanzanian Ministry of Health (MOH) 
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1.2 BACKGROUND 
Tanzania is estimated to have 2 million people living with HIV. HIV accounts for 29% of 
deaths in the country (WHO, 2006).  In Tanzania the first case of HIV was noted in 1983 
at Kagera region in the northern part of the country bordering Uganda. By 1986 all 26 
regions in the country reported HIV cases despite of all efforts to control the epidemic 
(THIS, 2008). In 2007 the prevalence in Tanzania was 6.2% (about 2 million people were 
living with HIV) this trend of infections shows that the disease is progressing in the 
country despite of HIV preventive education, behavior change strategies, voluntary 
counseling and testing plus treatment care and support interventions being in place. The 
increasing rates of HIV infections in Tanzania has compelled the Ministry of Health and 
other scientific institutions to work hard towards developing additional biomedical tools 
such as preventive HIV vaccines and microbicides  to complement ongoing  efforts to the 
fight against HIV/AIDS (TACAIDS-Tanzania Commission for AIDS, 2008). It was 
reported that women are more infected than men; male to female ratio of infection is 
1:1.22 (THIS, 2008; TACAIDS, 2008). HIV prevalence seems to be increasing by age 
and sex; most people affected are in the ages of between 30-34 for women and 35-39 for 
men. In 2007 there were 96,000 HIV related deaths recorded, urban areas have higher 
levels of HIV infection than rural residents (THIS, 2008; CIA, 2009; Tanzania National 
website). HIV vaccine is urgently needed in Tanzania because the disease has serious 
consequence to the country’s social economic and health situation. Treatment, care and 
support for HIV/AIDS including access to ART, is not yet available to all affected people 
in the country (TACAIDS, 2008). TACAIDS (2008) pointed out that developing an 
effective and safe vaccine will be a powerful tool in the fight against HIV.  
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Mbeya region is among the top three leading regions with high number of AIDS cases; in 
2005 there were 34,300 AIDS cases compared to 28,474 cases in Dar-es Salaam and 13, 
817 cases in Kilimanjaro which holds the third position (THIS, 2008).  In the study done 
by Mbeya Medical Research Programme (MMRP) in general population in 2002 the 
prevalence was found to be 16.6% (Arroyo et al., 2005). Although in the survey 
conducted by the National AIDS Control Programme (NACP) in 2003/04 HIV 
prevalence in Mbeya was estimated to be 14%  but still it remains high (Lyamuya, 2007). 
Incidence was high (7%) in women than male (5%) whilst the infection was 21% in 
urban and 11.5% in rural areas (THIS, 2008; Arroyo et al., 2005). AIDS related diseases 
are among the top three leading causes of deaths in Mbeya region (Mbeya Regional 
Hospital (MRH) Report, 2006). The region has consistently ranked high for several years 
for instance in a survey conducted from 2007 to 2008 reported that Mbeya ranked second 
with prevalence of 12.3%, after Iringa region with 16% prevalence (THIS, 2008). 
 
1.3. THE MBEYA HIV VACCINE TRIAL 
In 2005 MMRP was selected by the Ministry of Health and Social Welfare to become 
one of the sites to conduct HIV vaccine trials in Tanzania. The first  vaccine trial  to be 
conducted by the centre was a “A phase I/II  double blinded, randomized placebo 
controlled clinical trial to evaluate the safety and immunogenicity of a multiclade HIV-1 
DNA plasmid vaccine (VRC-HIVDNA016-00-VP) boosted by a multiclade HIV-1 
recombinant adenovirus-5 vector vaccine (VRC-HIVADV014-00-VP) in HIV uninfected 
adult volunteers in East Africa” (RV 172 Protocol, 2004). This was part of a multi centre 
trial with other centres in Kenya and Uganda. The trial started in July 2006 was 
 
 
 
 
 5
sponsored by the U.S. Military HIV Research Program (USMHRP). This trial involved 
inoculation of the vaccine (on trial) into the participants and subsequent following up and 
monitoring of participants for immunogenic changes. These procedures required high 
frequency of clinic visits compared to other studies where there was no investigational 
drug on trial. For instance in the two HIV cohort studies (mentioned earlier), participants 
were coming every three months for follow up at the clinic while in the vaccine trial they 
were supposed to visit the clinic every two weeks in the first two months then later it was 
every month for the next six months, there after participants were coming to the clinic 
every four months for safety monitoring and vaccination for 14-16 months. Participants 
in the HIV Vaccine Trial (HVT) were invited to attend information seminars where the 
study was introduced to the community and would be participants. Issues on aims and 
objectives of the study, duration, eligibility criteria were discussed. Some of the 
eligibility criteria were the participant has to be a legal resident of Mbeya aged between 
18 and 50 years. Should be available for appointment at the clinic for about 18 months 
from screening and must be in good general health. Also he/she must be HIV negative 
and at low risk for HIV. In addition the volunteer should be able and be willing to sign an 
informed consent form. 
Interested volunteers were registered to attend further briefing sessions where detailed 
information about the study (repeat of the above mentioned information plus all 
procedures that will take place, for example number of visits, vaccination, blood draw, 
HIV counseling and testing and medical examination). The study enrolled 60 participants 
in total. The study comprised of 14 visits including four vaccination days three DNA 
shots on day 1 day 28 and day 56 followed by Adenovirus-5 on day 168. Vaccination 
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schedule started in July 2006 and ended in October 2007. Until now November 2010 the 
participants are still being followed up by the study team following an extension of study 
time frame for safety and immunogenic monitoring. Participants who joined the study 
and attended the clinic for study procedures were compensated with 15,000 Tanzanian 
shillings (US$ 10) for transport and time spent at the clinic. During information seminar 
and briefing session there was no compensation only soft drinks were offered. 
 This qualitative study was conducted at MMRP clinic involving twenty volunteers who 
participated in the HIV vaccine trial conducted by MMRP from 2006 to 2007. 
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1.4. PROBLEM STATEMENT 
The recruitment and retention of HIV vaccine trial participants have imposed greater 
challenges to the MMRP study team compared to the other cohort studies. Our 
experience with the HIV vaccine trial during recruitment activities showed that only half 
of the volunteers who attended information seminars consented to participate in the 
vaccine trial. The main reason for that included the nature of the study itself where a trial 
vaccine was to be administered to study participants.  
There were lots of misconception and myths about the vaccine. Some of the concerns 
were the fear of being inoculated with a live HIV virus vaccine, that there was a hidden 
agenda concerning the safety of the vaccine and another concern was the trial being 
conducted in African countries (the idea of Africans being used as guinea pigs). These 
concerns were mainly heard from people who came to attend educational seminars but 
did not want to take part in the trial and also from people who were screened out in the 
early stages due to being ineligible for the study. Another concern from the volunteers 
was that too much blood drawn for laboratory purposes.  It was noted that there was a 
stigma attached to trial participation, for instance some of the people did not feel free to 
talk about their participation in the vaccine trial because community members were 
closely following up their health status. When a trial participant encounters any health 
problem it was directly linked to the vaccine administered to them. Unfortunately 
information regarding these concerns about study participation (valuable information for 
vaccine trial research) was not systematically collected nor well documented during the 
trial. The MMRP research team felt that understanding the experiences of those who 
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participated in the trial would be essential for future community engagement in order to 
improve the relationship and to support further HIV vaccine activities.  
 
1.5. PURPOSE OF THE STUDY 
This study will give the research team an insight into what the challenges are and if 
possible find solutions to them to improve the level of participation in future vaccine 
trials.  
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1.6 AIM AND OBJECTIVES OF THE STUDY 
1.6.1 AIM 
The aim of this study was to explore the expectations and the challenges of HIV vaccine 
trial participants at Mbeya Medical Research Centre in Mbeya, Tanzania. 
1.6.2 OBJECTIVES 
 To explore the expectations of HVT participants regarding participation in the 
study.   
 To describe the personal experiences of participants’ being on the trial. 
 To describe the challenges experienced by volunteers whilst participating in the 
study.  
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CHAPTER TWO: LITERATURE REVIEW  
2.1 INTRODUCTION 
The idea and excitement of developing an effective HIV vaccine in human beings started 
in the early 1980’s soon after the discovery of the virus causing HIV (Pitisuttithum, 
Francis, Esparza and Thongcharoen, 2006). Now more than 25 years later there is still no 
approved vaccine for human use due to a lack of knowledge about the virus and also 
because vaccine research is a long process that needs to be tested on healthy humans to 
ensure its safety and effectiveness after having been tested in animals (Pitisuttithum  et 
al., 2006; Cichocki, 2006).  On the other hand misconceptions and the varied beliefs of 
people towards vaccine trials poses the biggest challenges in the recruitment and 
retention of volunteers participating in HIV vaccine trials in different areas which are 
conducting these type of trials (Esparza and Bhamarapravati, 2000). Esparza and 
Bhamarapravati also argued that the development of an effective HIV vaccine would 
offer the best long term hope to control the HIV/AIDS pandemic, especially in 
developing countries which are hit on hard with the epidemic and thus there is a greater 
need for the vaccine.   
 
2.2 EXPECTATION AND WILLINGNESS TO PARTICIPATE IN HIV VACCINE 
TRIAL 
Lesch, Kafaar, Kagee and Swartz (2006) conducted a study in South Africa on 
community members’ perceptions of people participating in HIV vaccine trials. They 
noted that general mistrust of researchers and a lack of adequate information about HIV 
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vaccines were inhibiting factors in trial participation. Other concerns were the fear of 
becoming infected with HIV through vaccination and the negative reaction of family 
members and the community (Lesch et al., 2006).  
A study conducted in India by Sahay et al. (2004) explored the willingness to participate 
in HIV vaccine trials among low and high risk populations in Pune. This study reported 
an overall willingness to volunteer for HIV vaccine trials of approximately 48%. Health 
insurance and monetary incentives were among the factors mentioned that motivated 
volunteers to take part in the trial. In addition the authors pointed out that women and 
men at risk of HIV infection participated in the trial because they were aware of current 
HIV vaccine development efforts. It was reported that participants expected to benefit 
from the vaccine by being prevented from HIV. However peer and family pressure 
against volunteering and discrimination by community members against participation in 
the trial were some of the major concerns reported (Sahay et al., 2004).   
In another study on willingness to participate in an up coming HIV vaccine trial in South 
Africa by Paker (2006) altruism, medical incentives and hopefulness of being protected 
from HIV were among the facilitators to participation in HVT. However distrust to the 
research team, stigma and discrimination were mentioned as barriers to participation. In 
addition factors inhibiting willingness to participate were fear of safety and vaccine-
induced antibodies and misconceptions and myths about the vaccine itself (Paker, 2006).  
2.3 BENEFITS OF PARTICIPATION 
Insurance and monetary incentives were among the factors mentioned to motivate 
volunteers and were perceived benefits of taking part in the trial. Sahay and others (2004) 
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pointed out that women and men at risk of HIV infection wanted to participate in the trial 
because they expected to benefit from the vaccine (Sahay et al., 2004).  
In one study examining community and individual perceptions of research related to 
HVT it was revealed that  perceived benefits of participants were thought to be incentives 
for example financial compensation for participation. In another by Strauss et al., (2001) 
it was found out that participants thought the vaccine would build up their immune 
system against HIV infection, while others felt the vaccine will help other people in 
future by preventing them from acquiring HIV. Furthermore participants in this study 
believed that the vaccine on trial would be effective and thus would protect their 
communities from HIV epidemic (Strauss et al., 2001). 
 
2.4. VOLUNTEERS’ KNOWLEDGE AND PERCEPTIONS OF HIV VACCINES 
AND SAFETY  
Knowledge and proper information about HIV vaccine and its safety is among the 
important factors which influences volunteer’s decision to take part into the study. In the 
first vaccine trial in Africa which was conducted in Uganda by Mugerwa and the 
colleagues (2002) it was found that the community had fears that volunteers would be 
injected with HIV and that the vaccine might undergo dangerous mutations that could 
lead people to develop strange abnormalities in future. The authors pointed out that some 
participants in Uganda believed that the vaccine manufacturers chose poor countries for 
trials with the motive of spreading HIV among uninfected Ugandans to eventually wipe 
out the African race.  In a study conducted in South Africa by Stadler, Delany & 
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Mntambo (2007) it was revealed that a history of human right abuses under the apartheid 
regimen allowed the use of black South Africans due to their vulnerability, showing that 
there is distrust and negative attitude towards human research in African countries. In 
Congo Olin et al, (2006) found out that the dangers of an experimental vaccine and the 
stigma attached to vaccine induced positivity were the major concerns which inhibited 
willingness to participation. MMRP experienced the same concerns during recruitment 
and hence the researcher planned to interview the participants about their experiences on 
this matter to ascertain what information may help participants in future trials better 
understand the difficult issues like vaccine induced positivity. In a study by Strauss and 
others (2001) in the united state it was noted that people were unsure of the negative side 
effects that might occur as a result of participating in the trial. For instance there were 
concerns about the safety of the vaccine on trial, like would the vaccine harm them 
during the trial or in future! Vaccine induced positivity was such a big challenge 
experienced in the study conducted in Uganda. The volunteers who tested positive due to 
vaccine antibodies had to be offered special participation cards to protect them from 
being discriminated against for immigration, insurance and employment or other social 
issues (Mugerwa et al., 2002).  The risk of contracting HIV from the vaccine was one of 
the concerns in one of the preparedness studies for HIV vaccine trial (Strauss et al., 
2001). 
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2.5. CHALLENGES EXPERIENCED BY PARTICIPANTS IN HIV VACCINE 
TRIALS  
A randomized placebo-controlled trial known as Vax004, conducted in the United States, 
Canada and Netherlands in cities with high HIV prevalence in 1998 by Health Care 
Industry (HCI) showed that one in every five volunteers in HIV vaccine efficacy trials 
reported that they had at least one negative social impact in the three-year period of their 
participation in the trial (Hollander, 2008). 18% of volunteers experienced at least one 
negative social impact of trial participation while 3% experienced two or more. The 
majority 14% reported negative experiences and difficulties in interpersonal relationships 
such as negative reaction from partners, family members, relatives and friends. 
Unintentional disclosure of participation in the trial was a second common event and 
problems with insurance or employment were rare (Hollander, 2008). Furthermore 95% 
of the volunteers who became infected during the trial reported negative social impacts 
after infection. Some reported that friends and relatives had blamed the vaccine for the 
infection or for increasing the participant's susceptibility to infection (Hollander, 2008).  
In addition the study showed that reporting negative experiences was higher among men 
who were young and had had multiple partners shortly before entering the study than 
among those who had none or one partner (Hollander, 2008).   
 
2.6. ETHICAL CONSIDERATION IN HIV VACCINE TRIALS 
In Tanzania the Ministry of Health and Social Welfare released the National HIV vaccine 
strategic framework which was developed by Tanzania HIV vaccine research institutions, 
WHO-UNAIDS and The African AIDS Vaccine Programme (TACAIDS, 2008). 
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The framework is to provide guidance in the development and evaluation of candidate 
HIV vaccines by providing clear rules on regulatory approval, scientific and ethical 
reviews plus bio-safety and monitoring guidelines (TACAIDS, 2008). World Health 
Organization (WHO) and the Council for International Organizations of Medical 
Sciences (CIOMS) developed guidelines for human subjects’ research to ensure safety of 
study volunteers (Christakis, 1988). The guideline observes human rights and safety of 
the participant for instance before approval of the study a protocol for a vaccine trial 
involving details on safety of the candidate vaccine in terms of quantity and purity, being 
tested in animals or nonhuman primates to establish the ability and safety of the vaccine 
has to pass through the necessary regulatory authorities (Christakis, 1988). Also in the 
study of Ethical considerations in AIDS vaccine trials countries by Mahendele (2000) it 
was noted that the key cross cutting ethical issues were community engagement, ancirally 
care obligations, care and treatment of study participants, informed consent and 
confidentiality. These factors are very crucial in ensuring human rights and safety of the 
volunteers (Mahendele, 2000).  
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CHAPTER THREE: METHODOLOGY 
3.1 INTRODUCTION 
This chapter explains the process and methods used to conduct the study, the design of 
the study, the researcher’s role in the research centre, the study population and sample 
size, the sampling method, the data collection tools, the data analysis, the rigour and 
ethical considerations (general approach of the study). 
 
3.2 STUDY DESIGN 
The study was an explorative and descriptive qualitative study underpinned by a 
phenomenological approach to describe the experiences of volunteers who participated in 
a HIV vaccine trial at Mbeya Medical Research Centre. The reason for choosing this 
approach is that qualitative research is the most appropriate method in studying a 
phenomenon in its natural setting when the aim of the study is to understand people’s 
opinion, feelings or experiences and to make sense or interpret a certain phenomenon 
based on the meanings brought by people exposed to the phenomenon (Greenhalgh & 
Taylor, 1997). A descriptive study design was chosen because little is known about the 
phenomenon and the research seeks to describe the phenomenon. The design is relatively 
less time consuming and inexpensive compared to other designs (Beaglehole, Bonita & 
Kjellstrom, 1997).  
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3.3. STUDY SETTING 
Tanzania is located in the eastern part of Africa it has an area of 946,658 sq. km with 
population of 37.6 million (Census - 2002) about 80% of the population lives in rural 
areas (CIA, 2009; Bureau of African Affairs, 2007). Tanzania is among the poorest 
countries in Africa its GDP in 2004 was valued at $10 billion while the average income 
per capita was 300 USD and poverty is high. It is estimated that 36.1% of the population 
is living below the poverty datum line (Bureau of African Affairs, 2007). The economy 
of the country depends heavily on agriculture which employs about 80% of workforce. 
Swahili and English are both official languages with 69.4% Tanzanians being literate this 
was in 2002. The country is divided into 26 administrative regions/provinces including 
Mbeya (Bureau of African Affairs, 2007).  
Mbeya region lies in the southern part of Tanzania; it is on the highway from Dar-es 
salaam (capital city of Tanzania) to Zambia, Malawi and Congo and thus subjected to 
high interactions and mixture of people leading to increased risk to HIV infection. The 
region (province) is about 800 km from Dar-es- Salaam. The population of the Mbeya 
Region was 2,070,046 (2002-Census). The region has eight districts with urban, semi 
urban and rural areas. Most people in the region are small scale farmers (peasants) with 
some people employed by government or private sectors and some engaged in business 
(Bureau of African Affairs, 2007). Health services in Mbeya region consists of one 
consultant hospital, 17 hospitals, 154 health centers or intermediate hospital with capacity 
of conducting HIV testing and counseling plus 265 dispensaries these figure includes 
both public and private facilities combined (MRH 2005). 
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3.4. AN INSIDER APPROACH (THE RESEARCHER) 
The researcher was an assistant medical officer working at Mbeya Medical Research 
Programme as community outreach officer since 2000.  She worked as a recruitment and 
retention officer to most of the studies conducted in this centre (HIV related studies in 
high risk population as well as general population). She participated in previous studies 
focusing on recruitment and retention of participants in studies. In the HIV vaccine trial 
the researcher’s duties included organizing meetings and introducing the study to the 
community leaders. Also organizing and conducting information seminars and briefing 
sessions to potential participants together with study physicians. As a  retention officer 
she escorted the participants at home after vaccination, the intention was to know more 
about participants including where they lived for follow-up purposes especially when the 
study team could not reach them by phone. To this end she worked closely with research 
participants in previous HIV cohort study and also HIV vaccine trial.  It is based on the 
active involvement in recruiting participants, monitoring research progress and attending 
to participants’ queries and concerns that the researcher had an understanding of 
experiences and challenges faced by the HVT participants. For previous studies there 
were not many challenges in recruiting participants compared to the vaccine trial which 
was a new kind of study at the MMRP and it involved inoculation of drug/vaccine in the 
volunteer’s body. This posed the biggest challenge to the researcher in terms of 
recruitment, follow up and retention of participants especially due to community 
misconceptions. However knowledge of the participants was advantage to selection of 
respondents who were rich in information required for the study and the closeness to the 
participants was an advantage as it increased their freedom of expression. 
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3.5. STUDY POPULATION AND SAMPLE  
The study population in this study was 60 participants who participated in the HIV 
vaccine trial study in 2006-2007 at MMRP in Mbeya town. Respondents in this study 
were both male and female ages between 19 -49 years. Most of the respondents were 
married with children some were single and few were students. Initially the study was 
planned to interview 12 participants only but during the process of data collection and 
analysis the researcher noted that there was still new information coming up. Therefore 
she decided to continue with interviews to the level of saturation and finally interviewed 
20 participants.  
3.6. SAMPLING PROCEDURE 
Sampling is selection of individuals or units to be closely studied as representatives of the 
study population since it is not practical to study everybody (Katzenellenbogen et al., 
1997). Purposive sampling was used in the selection of study participants. Participants 
were strategically selected based on their knowledge of the study phenomenon (Bryman, 
2008). The selection considered participants’ demographic characteristics such as age, 
gender, education level, marital status and the location where the participant lived within 
Mbeya town. With regard to age the study selection criteria sought to include participants 
below 25 years, those between 25-45 years and above 45 years to see if they had different 
points of views regarding their participation in the trial. Both sexes were included that is 
11 males and 9 females both married and singles. The researcher wanted to get an insight 
on whether gender or marital state of the participant had any repercussion to him/herself, 
spouse and/or family. The sample also included those who lived near the clinic that is 
those living within 3km from the clinic and those living more than 3km from the clinic, 
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also educated and less educated participants were all part of the sample. Furthermore the 
interviews included three participants who became infected with HIV during the trial. 
The intention for this diversity in the group was to correlate and validate the information 
elicited from respondents. The study secretary assisted in selection of study participants, 
she knew them well and she is the one who dealt with their routine appointments and 
schedules. The participant enrollment register and follow up reports were used in 
selection of respondents as they contained necessary information to assist diversity in 
sampling (age, sex, marital status, HIV status, occupation and location). In addition the 
researcher and her assistant also worked closely with the participants; therefore the 
researcher’s knowledge of the area and participants contributed to selection of best 
subjects with the required information.  
3.7 DATA COLLECTION  
3.7.1 THE INTERVIEW  
Data in this study was collected by individual In-Depth Interviews (IDIs) conducted with 
study participants. IDI’s are very good in eliciting personal feelings and experiences of 
people although they are time consuming (Liamputtong and Ezzy, 2005). An interview 
guide with open ended questions was designed starting with simple and less sensitive 
question progressing to more sensitive questions. The factors that were to be explored by 
the study were participant expectations or motivational factors for participating in the 
trial for instance what compelled them to take part in the study. To understand whether 
they foresaw any perceived benefits, whether they had to ask permission from spouses, 
parents or family members and whether there were any fears/concerns regarding the trial.  
Furthermore the study was to explore the challenges faced by respondents at the clinic for 
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example study visits with regard to their personal plans, waiting time, the randomization 
issue like wanting to be in the vaccine group hoping that they would be protected. 
Likewise, the study looked at the challenges faced in the community where the 
participants lived for example rumors, misconceptions and the stigma attached to testing 
positive due to vaccine. The questions focused on the lived experience of the respondents 
as participants in the vaccine trial. The interview started with greetings, self introduction 
and informal discussion about general issues like work, business (depending on what was 
the respondents occupation), children and  giving him/her something to drink (coffee, tea, 
water or soda-soft drink) to build up good rapport and making the respondent relax before 
starting the interview. The questions asked were open ended and probing was allowed to 
shape the discussion/interview. (See the interview guideline attached in appendix no. 1).  
3.7.2 DATA COLLECTION PROCEDURE 
Permission to conduct this study was granted by the managing director at MMRP and the 
study community advisory board. Then during participants annual debriefing session the 
researcher discussed with the whole group of HVT participants about this study explained 
the purpose of the study, objectives, sample size and selection of respondents. There was 
no objection especially after explaining that they are going to be interviewed by staff in 
the study team. Training of the research assistant was done for two days by the 
researcher. The training focused on interviewing skills and ethics ensuring good quality 
of data. The research assistant was a nurse counselor working at the clinic who was also 
well known and trusted by the participants. The researcher chose her because she was an 
experienced counselor and interviewer and the researcher felt that respondents will be 
free talking to her (the known nurse counselor) than to a new person especially on 
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questions focusing on their HIV status. The counselor has also worked in previous studies 
at the research centre as an interviewer for the past four years.  
With assistance of the study secretary one day before their routine visit to the clinic the 
selected respondent was contacted by phone. It was explained to the potential participant 
that he/she was requested to participate in the interview the next day when they reported 
for a clinic schedule. Prior appointments were made to prepare the respondent and avoid 
inconveniencing their daily schedules. Respondents were invited to the interview room 
only after finishing all procedures required for their routine visits.  After creating rapport 
and ensuring confidentiality the information sheet was read to the participant and if 
willing to go on with the interview she/he was given a consent form to read and sign. 
Confidentiality was ensured and respondents were encouraged to ask all questions they 
wanted to before signing the consent form. All interviews were conducted at the clinic in 
a private and quiet room. The interviews were prepared in English then translated into 
Swahili (Tanzanian national language), all interview were conducted in Swahili although 
some participants could speak English.  The interviews were audio tape recorded with the 
participant’s permission. In addition the interviewers used a pen and notebook to write 
down important events/aspects that cannot be picked up by the recorder during the 
interview like sighing, any signs of uncomfortably, relaxation or tiredness. The 
interviews were conducted on weekdays (Monday to Friday); most interviews took 40-60 
minutes (50 minutes average). Since these interviews were conducted on their routine 
visits bus fare and time compensation were covered as part of the trial routine 
compensation.  In two of the extra interviews from the original planned sample the 
researcher had to conduct the interviews by phone because these participants had moved 
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out of Mbeya one for further education, while another was married in another region. The 
interviews conducted by phone were more expensive and time consuming in terms of 
tracing the respondents and persuading them to agree for an interview as the researcher 
felt it was crucial to understand their reasons for withdrawing from the study as they had 
an implication to the outcome of the study. On the other hand it was easier to clarify and 
paraphrase question in the face to face interview than phone interviews. However the 
findings from these interviews were contributive to this study and future vaccine trial at 
MMRP. In another situation the researcher conducted an interview in the respondent’s 
office because she dropped out of the study she could not come for routine schedules and 
it was also crucial to understand her reasons for dropping out because the respondent was 
among the volunteers who seroconverted during the study. The research sought to 
understand whether her dropping out was connected to seroconvertion. The interview had 
to be brief as she had to lock the door to avoid interruptions. This experience shows that 
in qualitative research sometimes appointments and interviews do not take place 
according to the plan therefore flexibility and adaptation to different situation is 
necessary.  
3.8. DATA ANALYSIS 
Qualitative research is not usually guided by hypothesis and each qualitative research is 
unique thus making the final report for each qualitative study also unique depending on 
the inquiries made by the researcher (Willms & Johnson, 1993). In this study all collected 
data were transcribed verbatim and then translated back from Swahili into English by the 
researcher and the research assistant within one week of interview to ensure that no 
valuable information was forgotten or excluded. Themes for this study were prior 
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formulated based on the aim and objectives of the study, exploring expectations and 
experiences of HIV vaccine trial participants at MMRP. There after the data collected 
was organized into themes and codes to facilitate analysis and interpretation.  
The data was analyzed using a thematic content analysis (comparing the contents in each 
sentence from the respondents with the themes identified in advance by the researcher).  
The themes in this study were seeking to understand the experiences of respondents to the 
whole process of participation in the HVT, from entering the study to the end of the 
study. Themes focused on education seminars, expectations, motivation and reaction of 
significant others plus the challenges encountered during their participation. In addition 
the research sought to understand participants’ opinion towards HIV status and 
seroconversion plus participant’s general opinion about HIV vaccine trials (See attached 
themes and codes-Appendix 2). 
3.9. RIGOUR 
The researcher used purposive sampling to select sample units with relevant information 
to the study aim/goal. The researcher knows well the participants as she works in the 
research centre on daily basis thus ensuring right selection of study participants which 
included a diversity of people in the group. For instance taking consideration of different 
age groups (young, middle age and elders) gender both male and female were 
interviewed, marital status and location based on distance from the clinic was considered 
to ensure trustworthiness and best triangulation of information. In addition the interviews 
were conducted in a private room to offer reliable privacy and freedom of expression to 
respondents and all interviews were audio recorded transcribed and translated to make 
sure that nothing mentioned by the respondent is overlooked to ensure confirm ability. 
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Furthermore a cross section of the participants’ sex, age, distance, HIV status and 
education helped to ensure inclusiveness of the study population and at least two 
interviews were conducted in each group.  In addition the researcher interviewed some 
participants who had relocated to other places far from Mbeya town also those dropped 
out of the study to ensure that none of the necessary information is missed concerning 
participation in the trial. 
 
3.10. ETHICAL CONSIDERATIONS 
The study was approved by the local authorities at Mbeya Medical Research Programme 
and the region research ethics committee. The study did not involve any threatening or 
invasive procedure that was likely to cause harm. However the vaccine trial counselors 
were always around in case the need arises as the interviews were conducted in the clinic 
during working hours.  
Respondents were informed that participation in this study was completely voluntary.  
The study’s aim and method were well explained to all potential study participants in the 
information session. Potential participants were given a study information sheet with 
details about the study they had to read and sign the informed consent form before taking 
part in the study (appendix 3). Volunteers were ensured of confidentiality and anonymity. 
Due to sensitivity of the study it was clearly explained that the participants that they may 
refuse to answer any of the questions they do not want to and they were free to withdraw 
from the study at any time without negative consequences or losing any rights which they 
were otherwise entitled to. 
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 CHAPTER FOUR: FINDINGS  
4.1 Demographic profile of study participants 
Participants were purposively chosen to suit the aim of the study. Diversity in the study 
sample was ensured. The researcher interviewed 11 male participants and nine female 
participants, of these 12 were married and eight were single. Five participants were below 
the age of 25 years, 11 participants were between 25-45 years old and 4 participants were 
over 45 years. Eleven participants lived within 3 km of the clinic while 9 lived more than 
3 km from the clinic. Ten participants had a primary school education level, 5 had a 
secondary school education and the other 5 had a college level of education (see the table 
below. 
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Table 1: Demographic profiles of the participants: 
 
Characteristics variables No of 
participants 
Percentage 
Gender 
Male 
Female 
 
11 
9 
 
55% 
45% 
Marital status 
Married 
Single 
 
12 
8 
 
60% 
40% 
Age 
Below 25 years 
Between 25-45 years 
Above 45 years 
 
5 
11 
4 
 
25% 
55% 
20% 
Distance from the clinic 
Within 3 km 
More than 3 km 
 
11 
9 
 
55% 
45% 
Education level 
None or below Primary school 
Primary school level 
Secondary school 
College/other institution level 
 
1 
10 
5 
4 
 
5% 
50% 
25% 
20% 
Occupation 
Petty business 
Students 
Employed 
House wives 
 
10 
3 
4 
3 
 
50% 
15% 
20% 
15% 
HIV status 
Negative 
Positive 
 
17 
3 
 
85% 
15% 
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4.2 Entering the study and clarity of educational seminars 
There were mixed views about joining the study as some participants feared and others 
were clear, respondents pointed out that participation in the study was completely 
voluntary. Potential participants attended a detailed educational seminar before they 
decided to take part in the trial. It was also noted that most of the volunteers who 
participated in HVT had been participants in other cohort studies conducted by MMRP. 
Respondents reported that some areas of education were clear but some areas needed to 
be emphasized and more clarified for example, a 23 years old female participant, and 
college student pointed out that…  “It was not very clear when you said, we might test 
positive…. but we shouldn’t worry…. I guess more clarification is needed there…”  
As to the experience about entering the study the participants reported hesitating before 
attending educational seminars. For example a 34 years female participant married to a 
bus driver remarked “initially I was not sure whether to enter the study or not… I was 
hesitating because I was not sure if there is completely no risk in participating in this 
kind of trial… However after getting detailed information I decided to join” 
Also a 42 years old male participant who is married and a father of four children also a 
driver in a private company remarked … “I asked the facilitators so many questions…”  
The interviewer asked him whether the questions were answered to his level of 
satisfaction; the response was   “ooh yes otherwise I would not participate” 
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4.3 Expectation and Motivation to participation. 
This part of the interview explored what compelled the volunteers to participate in the 
trial, also to know whether they had any concerns or worries and whether they had to ask 
permission from their spouses before deciding to take part in the trial. 
4.3.1 Motivation factors and perceived benefits 
Most of the respondents remarked that they joined the study because they wanted to 
check their HIV status and to receive free medical care which was part of the benefits of 
participating in the study. A 34 years female participant, married and mother of two 
working as a secretary at the university said … I wanted to monitor my health status… I 
know I will be checked more frequently… However some respondents mentioned that 
they wanted to be part of the world’s effort in finding an effective vaccine for HIV.  A 44 
year old male evangelist remarked:  
...I know that there were some diseases like small pox which was a disaster for 
decades, but the vaccine was the only measure that was successful in eliminating 
it…. So the same with HIV, I feel that if the idea of a vaccine succeeds, it will be a 
savior for our nation … adults and even youngsters are being wiped out by the 
disease. 
 
Another female respondent a 45 year old married house wife explained:  
My biggest motivation was medical health care… but also I thought if the vaccine will be 
successful it will benefit me and if not me then my children or grandchildren. 
Some participants believed that they would be protected from HIV infection, for example 
a 25 year old single female reported…  “The vaccine must have some protective effect”  
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Also a 24 years old male college student had a similar expectation he said “...if we were 
allowed to choose I wanted to get the real vaccine… I know it will add some immunity in 
the body…” 
A female participant aged 33 years and married reported “... since it was the first HIV 
vaccine to be tried in our country... I thought it is a big achievement … actually I’m 
proud to be part of this trial.   
She further said “we were told that every research passes through several stages for check 
before approval is given to conduct the study… (Silence)… I believe our government is 
not asleep, it cannot allow something harmful to be introduced in the country” (this 
respondent also had participated in other studies at MMRP). 
4.3.2 Concerns/Worries to participation on HVT 
Respondents had differing views on the vaccines. Whilst some had little knowledge of 
the vaccine, others believed that all vaccines had some parts of the virus or bacteria in 
question. A 44 year old married male   a street leader in one of the areas in town said “we 
used to know that vaccines are made from the bacteria or the virus responsible for the 
disease intended to be prevented… so we thought the same applies to HIV vaccine”  
 
A 45 year old married female who had participated in two HIV cohort studies conducted 
at MMRP, pointed out that “…No, I did not have any worries, I believed what the doctors 
told us in the seminar and since I had been a participant at MMRP for like three years, I 
trust them not to do anything that will harm the participants in any way, if that was the 
case they would have done it long ago.” 
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Also a 33 years old business man said … Initially I was worried about the safety of the 
vaccine… what if it harms me or I real get sick! But the seminar was good it answered 
most of the questions I was asking myself” 
 
4.3.3 Permission from partners/spouse 
Most respondents whom were either married or living together for more than two years, 
pointed out that, they had discussions with their partners before participating in the study. 
Female participants, especially, had to get permission from their husbands.  A 34 year old 
female secretary explained: 
 … After attending the information seminar, I had to tell him the details of the study 
otherwise he would have killed me if he heard that I participated without his permission  
 
It was also reported that in some couples where by one participated whilst the other 
partner did not, it lead them into serious problems in their marriages. A 38 years old male 
participant, married and a shoe seller admitted that “... my wife and I had a serious 
quarrel about my participation in this trial, especially after hearing the rumours 
concerning the vaccine; she would not allow me to touch her because she thought I am 
already infected by the virus from the vaccine…The situation got worse. We had to talk to 
the PI (Principal Investigator). He explained to us and together we went through the 
informed consent form…. she understood and things went back to normal. But I tell you it 
was very tough at home… (laughter).   
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4.4 Personal experiences at the clinic 
4.4.1 Appointments and time at the clinic 
 Most of the participants said they were satisfied with their appointments and other 
procedures at the clinic. A secondary school student aged 19 said; “for me I was okay 
with the whole arrangement at the clinic and schedules, we were told from the beginning 
that doctors will monitor us very closely…. So how can they monitor you if you don’t 
come here…? 
 
 Another participant, a 26 year old male laborer said …yah initially appointments were 
like too many…though not to the level of inconveniencing my duties, but I knew it was for 
good intention.  
 
However participants who were students during the study reported that they had to adjust 
their routines to accommodate study appointments, for example a 24 year old male 
student said “I had to change my (school) time table… especially for morning session on 
days of appointment  ... but it was okay” Also a secondary schools female student of 21 
years said… “at times I missed morning sessions to come at the clinic … in the evening I 
had to copy notes from my classmates”. 
Some respondents felt that the time spent at the clinic to complete all procedures in a 
particular visit was too long, especially in the initial visits where they had to go through 
the informed consent process, the test of understanding, a medical examination and 
counseling.   The evangelist said; “ Yes …yes…about that…, waiting time was too long in 
some of the visits, like in one visit I remember coming at  eight o’clock in the morning 
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and I left the clinic at half past three in the afternoon…this is  not convenient for 
someone employed”. 
On the other hand there were some participants who were fine with schedule and visits, 
for example a 33 years old business man remarked… It was fine with me… I just live 
behind the clinic and am not so busy in most of the mornings. 
4.4.2 Trial procedures (Vaccination, randomization, blood draw, vaccine induced 
positivity)  
The participants acknowledge that initially they were concerned about safety due to 
vaccination, particularly... A female participant 31 years old married with three children- 
house wife reported …I had some fear especially with the first vaccine shot… I thought 
ooh lord why did I bring my self into this…So I went home till next day... I was fine, three 
days later nothing wrong, and then I relaxed.    
Participants reported that it took time to fully understand the rationale and safety issues in 
the vaccination although they were still reporting for further doses. One respondent 
mentioned …the second one I still had some worries but the third and forth doses I was 
completely at ease. Furthermore respondents reported that they did not experience any 
serious side effects from the vaccination, for example a 40 year old female petty trader 
remarked, ….I did not feel anything like fever or any kind of shock  apart from mild pain 
at the site of injection.. 
However some participants experienced minor side effects, a married 42 year old 
housewife stated that, “…..It was nothing serious ….I had a headache ….it lasted for like 
four hours”   
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With regard to randomization, participants reported that they understood why they were 
divided into two groups (a vaccine group and a placebo group) for research purposes.  A 
25 years female participant who was single a vendor pointed out... It was clear at the 
seminar that we have to be in two groups so that they can compare the results. 
 
On the other hand a 24 year old male college student stated …Honestly I wanted to be on 
the vaccine group …. But I was not... I believe the vaccine has some protective effects.  
Participants had different perceptions regarding vaccine induced positivity (false 
positive). Some accepted this situation while others were concerned. A 31 year old 
female secretary explained, …I did understand well the seminar so I thought it was just 
fine, so long as it is not a real infection. 
 On the other hand a 49 year old business man reported, …I was a little skeptical and 
asked lot of questions on this area…at last I felt it is fine since it is a research…let it be”.  
Others felt that there was something hidden behind this positivity, for example a 24 year 
old young man said;  
False positive mmh! … you never know… maybe this would be for 
real…….honestly I was worried  three months after vaccination I went to a VCT 
centre to test my blood , just to check if I will test positive or not” I would have 
also known whether I was in the vaccine or placebo arm… 
Few respondents reported being uncomfortable with the amount of blood drawn for 
laboratory purposes, for example one  food vendor, a 34 years old lady reported … aah! 
The blood taken was too much …. (silence)… what if someone has low levels of blood!! 
(The blood drawn per visit was about 140- 150 mls).  
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4.5 Experiences at home with family and friends/neighbors 
4.5.1 Free to tell others about their participation  
Most of the participants said they were free to tell others of their participation in the trial, 
although some were mocked by their neighbours and friends who told them they were 
risking their lives for a little money. It was part of the study duties to escort participants’ 
home after vaccinations if they wanted to.  One participant, a 39 year old male participant 
who worked at a local garage who rejected the offer to be escorted home by a research 
vehicle explained, 
 At the beginning, I did not tell anybody.., even my wife did not know… when you 
(study staff) wanted to escort me home after the first vaccination…. I 
disappeared; actually I did not want you people to follow me home because I 
knew if this happens my wife will start asking questions. 
The interviewer asked for the reasons not to tell his wife; he said..,  
Actually in the beginning even myself I was not so much trusting what you people 
(the study team) told us in the seminars…. so I was in the state of let me wait and 
see for some time… until everything is right… when we built trust… after being 
vaccinated with two doses I saw nothing has happened to me or others, from there 
I was free to talk about the study at home and even at work.  
In some areas people in the community were asking questions about the study. They 
wanted to know the details.  A 37 years married female participant remarked, 
I was free to tell my friends… they asked me questions, I  answered them 
according to what we learned in the informational seminars… some promised to 
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attend information seminars, others just mocked me… but I did not care as I know 
what I wanted and had participated in several studies at MMRP. 
4.5.2 Reactions of significant others (Spouses, family members, neighbours and 
friends). 
 
Some participants admitted having a difficult time with their spouses, families and 
friends as there was a stigma attached to participating in the trial. They were especially 
skeptical about the presence of the white investigators in the trial. For instance a male 
tailor who was 39 years old and married summed it all:  
My (relatives) and my wife had no problem and we both took part in the 
study…but the neighbours huh! it was hell.., especially those who were screened 
out at the initial stages of participation. For example one said; I tell you, those 
whites (European white researchers in the MMRP trial) are bad news, they are 
intending to inject us with the virus, they have a hidden agenda.  I’m warning 
you… You will die for a little money. 
Participants reported that most of the rumours and misconception going around in the 
community concerning the vaccine were coming from people who had not attended 
education seminars or they had wanted to take part in the trial but were filtered out during 
screening visits (they were ineligible). A 23 years old lady, single a college student 
reported that:  
Friends and neighbours  said we are being  injected with  HIV virus, we will soon 
fall sick, we are very stupid to involve ourselves in something very risky, why are 
the whites( the people coordinating the trial) not conducting this trial in their own 
 
 
 
 
 37
countries! They are coming to Africa to kill us”... but actually they didn’t know 
the truth about the trial. 
A street leader who together with his wife participated in the trial reported the neighbors 
telling him … you and your wife are going to die due to participating in the whites’ trial.  
A male respondent 25 years a petty trader and also married pointed out;; “I realized the 
people who started those rumours wanted to participate…they even attended educational 
seminars but they were found not to fit into the study (ineligible)... so they decided to 
spoil the names of those who continued with the study” For example someone at home 
said openly that… I listened to their (the research team) information seminars but at last I 
knew they have a hidden agenda. 
 
A lady 27 years old a housewife explained;  
…..we were so much insulted by our neighbours….they said to us… You are even 
told not to become pregnant…but you are still blind … it needed one to be strong 
to stay in the study to the end. 
A 39 years old male, working at the garage narrated,  
I tell you there were so many rumours in the streets, it was a big problem to many 
participants… some wanted to drop out of the study… It was not easy for some of 
the couples; they had to sleep in separate rooms. 
Some respondents pointed out that they did not care much what other people thought so 
long as their spouses were fine with them participating in the trial.  A 28 year old married 
male taxi driver explained:  
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My wife and relatives had no problems because they know and trust me that, I 
would not put myself into something dangerous …and that was all that mattered 
to me, other people were just talking because they did not know what was exactly 
happening at the research centre …… (silence) so I just ignored them. 
It was also reported by respondents that some people thought there was a hidden agenda 
to sell the blood to America because the study was funded by the USA military. 
 
On the other hand respondents appreciated the health care provided by the research team 
when they fell sick. For instance, a 49 years old male participant, a shoe shiner who was 
married and a father of three children, he had some serious health problems the study 
team provided the necessary medical care he appreciated,  
If I were not a participant in MMRP centre I would have been dead by now, 
because with that sickness, I would not have that amount of money needed to go 
to Dar-es Salaam for treatment, but with the support of research centre, look at 
me as you can see, I am healthy and feeling good again .  
He continued, 
“When I started having fits the neighbours said the vaccine has already affected me and I 
will soon die, even my wife was so worried”  
This participant was initially well and passed all eligibility criteria during screening 
phase, then three months after enrolment he developed a problem of having fits which 
sometimes ended up with him losing consciousness. He was referred to the National 
Hospital in Dar-es Salaam (over 800 km from Mbeya). The research centre hired a flight 
for him and paid all costs for investigation and treatment. In addition he was given a 
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doctor from the team to escort him. He was admitted to Muhimbili National Hospital and 
after Computer Tomography scan it was found that he was having Taenia solium 
(cysticercosis) in the brain. He was treated and recovered fully.  
 Other respondents felt that the people who were spreading the rumours were being 
stubborn or jealous. The male street leader reported that;   
Some people, who were saying bad things concerning the trial, are just being 
stubborn… They knew that one has to be HIV free to participate, and they can’t 
dare go for a HIV test…. and others were just jealous because they were not 
benefiting from the free treatment the participants were entitled to.  
 
4.6. HIV status, discordance and seroconversion during trial 
Participants were free to discuss their HIV status. They felt that HIV/AIDS was now a 
common problem and people were free to talk about it. There were some participants 
whose partners were HIV infected while they were not (discordant couples). A female 
student aged 23 years  explained, … We can discuss anything I’m so free…. even if I was 
positive I would have just told you, nowadays this is no longer something to hide….  
A 49 year old male participant was happy that he knew his status but the problem was his 
wife, he spell out …. Am happy that….I’m HIV free… but I don’t know my wife’s state …. 
She does not want to hear anything about HIV testing…..”   
Some participants were in a state of confusion they felt that may be they were infected, it 
was just the tests that were faulty and not giving the right results. For instance a male 
participant 42 years old and married also a driver explained;  
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...at times I do not understand what is happening in my life, because my wife is 
HIV positive for some years now….. but every time I come here for my 
appointments the counselor tells me that I’m HIV free … so I don’t know… why 
am I still negative … we do not use any protection. 
A male respondent 26 years old who is a laborer at the main bus stop reported; …I guess 
God protects me …..we found out  that my wife was HIV infected during her antenatal 
attendance three years ago….I’m still negative… and loving my wife….. so I think am 
just lucky…” 
During the two years of participant follow up in the study, some participants who were 
initially HIV negative, seroconverted while in the study.  These respondents had different 
opinions for example there was a respondent who blamed the vaccine as the cause of his 
infection.  A 28 years old male participant, married working as a clerk remarked, 
What I know is that, I entered the study being HIV free and after the third vaccine 
they told me I was infected…. He continued “... I really wonder how come I’m 
infected while my wife is not and she has just delivered a baby.   
The participant was bitterly complaining that it was being in the study that caused his 
change in status, due to its sensitivity this matter was discussed in the community board 
meeting, together with the study team they investigated the participant’s sexual behaviour 
and it was found that he was at high risk of acquiring HIV due to multiple partners. 
While the other infected respondents felt that they were infected because they were 
exposed to HIV by their partners’ behaviors. For instance a 32 years old, female 
participant a mother of two, employed in the private sector stated;   
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I joined the study because I wanted to have a thorough check of my body, ... I had 
been doubting  my husband’s health for quite some time … at the beginning  they 
told me that I was negative…, I was so happy….. but after one year... I came to 
the clinic and the counselor told me that I was infected, (silence)…. I was so sad 
but I was not surprised as I knew my husband’s behaviour and he has been 
suffering from questionable skin infections. … I have learned to live with the 
infection…I hold no grudges on him. 
One married female respondent of 36 years narrated;  
I was not shocked by the news because for some months my husband and I were 
not on good terms...he was not sleeping at home… he was going out with other 
women…I knew I was in danger and that’s it… 
 All seroconverted participants are receiving supportive counseling and treatment care at 
the treatment centre neighboring MMRP within the Mbeya consultant hospital campus. 
 
4.7. Challenges to participation and being in the study to the end 
The study was quite time consuming, with numerous visits for safety purposes for 
instance close monitoring of participant, regarding any side effects or problems due to 
vaccination and the participants is well (all vital signs are normal) before allowing 
him/her to go home. Participants were to stay at the clinic for at least four hours in the 
screening and vaccination visits because they were to do informed consent papers, 
clinical examinations, drawing of blood, counseling and observation after vaccination. It 
also required the participant to come in the morning hours which were working hours for 
most people.  
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A female respondent whose business included selling spices from home explained …It 
was fine for me… I don’t have much to do at home any way..., and I live just behind the 
clinic. As for benefits, she remarked … aah! Yah! My business is small…. so with the 
money I received, I use to buy some basic home needs … as it is not much… 
The participants who lived 15 km from the clinic faced the problem of transport in the 
morning, a lady aged 28 living with her parents explained, …In order to reach the clinic 
in time, I had to leave home very early because it is far and taxis are congested in the 
morning… but it was okay since it is not every day. 
 Remaining in the study to the end was also a challenge to some respondents, especially 
to those with a busy schedule or those who traveled a lot for business purposes.  A 33 
years old married businesswoman, narrated ... it was hard for me to abide with the 
scheduled visits especially in the beginning because I travel a lot... at times I miss my 
appointments…  
 
This also applied to students who had to miss some of their classes/sessions to attend the 
clinic. For example a student in one of the colleges in Mbeya who is 24 years old 
reported …my appointments were mostly on Monday or Tuesday, these days we are busy 
at the college… so I would come late to the clinic… or choose to miss one or two 
sessions… 
 
The study indicated that participants who dropped out for different reasons, either 
moving out of Mbeya town due to work, business or family reasons. None of the 
interviewed participants had a reason directly related to the study.  A female participant 
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32 years old married also a secretary reported …I had to stop because I got a better job in 
Dar- es Salaam… I could not make it for all appointments because it is far.  
 
In another case a 26 year old female who was single at the time she joined the study 
said… My fiancé lived in Arusha… he came and wanted me to go with him... So I had to 
withdraw from the study…. I would have continued if I was still in Mbeya.  
 
The constant challenge mentioned by respondents was dealing with the rumours, 
misconceptions and stigma of community members (relative, friends, and neighbors) 
regarding their participation.  A 42 years old male respondent, a driver explained  ... I tell 
you it needed a strong heart to keep on coming here... others despaired due to what 
people said about this trial… 
 
4.8 Participant’s opinion of the trial in general  
Respondents acknowledged that the care provided to them at the clinic, especially when 
they fell ill, was of high quality. They felt safe and in good hands. This wiped away all 
the fears and feelings that there was a hidden agenda to this vaccine trial 
A 45 year married male explained …the care we are getting here is not available in the 
public hospitals…. … so I see it as a big advantage for my being in the study”.  
As for how to improve future HVTs most of the participant said that the order of 
procedures from the reception to the end of the visit was fine with them. Regarding the 
frequency of visits, they pointed out that it was fine since it was important to their safety. 
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They felt we should continue like that. For example a single female petty trader 25 year 
old reported,  
… I feel that the whole arrangement at the clinic …including appointments is well 
organized, because it is important to our health… one has to organize his/her 
schedule because we are given our dates to come in advance. 
 
 However an evangelist reported; … In future you should try to minimize waiting time to 
allow people to continue with their daily activities.  
 
A 42 years old male bus driver giggled then spells out …I am not sure whether it is the 
right place to say it…. But if possible you have to increase the amount of compensation… 
the study takes so much of our time. 
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CHAPTER FIVE: DISCUSSION 
This chapter discusses the findings from the study which was designed to explore 
expectations and challenges experienced by HIV vaccine trial participants at Mbeya 
Medical Research Centre. The objective of the study was to describe personal 
experiences and challenges encountered by the volunteers whilst participating in the trial. 
The key themes identified will be discussed under separate headings. 
Entering the study 
Most of the participants in the HVT participated in other HIV cohort studies conducted at 
MMRP. The study revealed that entering the vaccine trial was completely voluntary; 
people were invited for educational seminars. Interested individuals registered their 
names and were given appointments for initial procedures for enrollment (screening 
visits).  Informed consent form was provided to all volunteers to read and sign before any 
procedure. According to most respondents the educational seminars were clear and 
understandable however some participants indicated that they wished to have more 
details on some areas of the study like randomization, placebo and especially the vaccine 
induced postivity (why this happens and how could it be differentiated from a real 
infection). These findings were in line with the findings by Strauss et al., (2001) where 
the study indicated that people would require more information and assurance on these 
aspects before they decide to participate in a HVT.  Therefore there is a need to improve 
the package of educational seminars to address these concerns and also giving adequate 
information. Also clarification of misconception before enrollment will motivate 
volunteers and increase enrollment uptake in future studies. 
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The study showed that the community develops trust in a research centre based on its 
previous successful research activities and the period of its existence in the community. 
In the study by Lesch, et al., (2006) it was noted that mistrust to the researchers was a 
barrier to entering the study, however the findings in this study showed that trust to the 
research team was an important motivating factor for participation. It was reported that 
some of the participants had been volunteers in other cohort studies conducted by MMRP 
since 2000. They reported that they knew and trusted the research centre too well to have 
any fears or worries concerning the vaccine on trial. 
It was also noted that using the radio or television to invite or educate people on vaccine 
trials increased the trust of the participants to the research centre because they believed 
that for something to be in the trusted media it must have been approved by all important 
authorities. These findings are very important to the research institution to assist in 
building trust to the participants and research communities and thus increasing 
willingness of people to volunteer participation in studies.  For instance in one of the 
studies in South Africa by Stadler and others (2007) it was noted that there was mistrust 
and negative disposition towards medical research. Therefore mistrust can be minimized 
by the use of media like television, radios and newspapers and this requires more 
research on how far/much does the media influence community participation in studies. 
However there was mistrust of the organization because it was funded by American 
military and white investigators. Since there is a history of colonialism in African 
countries there was a feeling that there is a hidden agenda behind research activities and 
thus having an implication to participant recruitment.  
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Motivation factors, perceived benefits and perceived threats 
The study indicated that most respondents felt that they wanted to be part of the world’s 
effort in fighting the HIV epidemic and some expected that the candidate vaccine would 
be successful in protecting their offspring in the future. The participants acknowledged 
the loss of their loved ones to HIV/AIDS and they really wanted to do something. They 
believed that a vaccine was a powerful tool in fighting serious diseases. They referred to 
small pox and polio as evidence. Free medical care was among the pull factors to 
participation in the trial. This is in line with the study conducted in the USA on 
preparedness to conducting a phase III vaccine trial where it was pointed out that free 
medical care, altruism  (self-sacrifice) and expectation for the vaccine to work were some 
of the perceived benefits for the respondents (Strauss et al., 2001).  
Strauss and others (2000) noted that financial or other practical compensation were 
mentioned as perceived benefits for taking part in the trial. This also became evident in 
this study some participants reported financial compensation as part of the benefits 
expected. These findings has an implication on willingness of people  to participate in the 
study it shows that people  have things to consider in making decision to participate in 
trial based on what they believe as benefit or threat in the phenomenon in place. The 
participant in this study most of them participated in other studies conducted at MMRP 
thus they were privileged with benefits of free medical care as well as compensation. On 
the other hand ethical bodies are concerned with compensation or incentives to study 
participants. It was pointed out by Grant & Sugarman (2004) that there is a confusion 
regarding appropriateness of using incentives in research with human subjects; it is 
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considered as form of coercion or inducement especially in cases where people are not 
ready to participate if the amount for compensation is small.   
 
On the other hand the study revealed that some participants took part in the study 
believing that they would be protected from HIV infection. This shows that there was a 
gap or unclear information in our educational seminars. May be the volunteers did not 
understand that the candidate vaccine was still on trial and it was not known whether it 
had the ability to protect or not. This is probably the reason some people got infected 
because they thought they were protected. Similar findings were pointed out from an HIV 
vaccine safety and immunogenicity trial conducted by Chesney, Chambers & Kahn 
(1997) in San Francisco to examine changes in sexual risk behavior that are associated 
with risk of HIV transmission.  It was found that participants had participated in the trial 
hoping that they would be protected from HIV infection. Respondents expressed that they 
had some fears/worries concerning the vaccine on trial. For example they feared getting a 
real infection from the vaccine because they knew that most of the vaccines were made 
from the bacteria or virus responsible for the particular disease. Some were concerned 
with the safety of the vaccine; they had fear of the side effects also some participants 
wanted to know how long the false positive will remain in their bodies. Similar concerns 
were pointed out in the study by Hollander (2008) that fears of infection, mistrust of the 
research team and a lack of detailed information about the trial were some of the setbacks 
to a willingness to participate in HVT. The same findings were also noted in the study 
conducted in South Africa by Lesch and the colleagues (2006). 
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.As for family issues in relation to participating in the trial the study showed that there 
were some couples which experienced serious problems due to one partner participating 
and the other not, following rumours and misconceptions which were circulating in the 
community concerning the trial. It was found that participants who were married or living 
with partners’ especially female participants had to ask permission from their partners 
before participating in the study.  
These findings have implications to individual’s freedom to decision making. In most 
African cultures/customs women and children are supposed to be submissive to their 
husbands and parents. Traditionally in Tanzania a wife has to consult or ask permission 
from her husband before doing anything whether is for her own or family benefit and 
thus interfering with one’s autonomy to making decision. More education and 
sensitization is needed to the community to improve people’s understanding of research 
issues and freedom to decide. In the study by Woodsong (2004) on covert use of topical 
microbicides in women it was revealed that a woman’s decision to use the microbicides 
with out involving the partner was not simple especially in the context where men control 
house hold finances and wife is completely dependant to the husband. It was pointed out 
that decision to use was interfered by fear of repercussion on discovery from the partners 
(Woodsong, 2004). 
 
Personal Experiences at the clinic 
As for experiences at the clinic the study found that the most participants were 
comfortable with appointments and procedures attached to HVT. Although visits were 
very frequent in the beginning they understood that it was for safety monitoring purposes 
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and they thought that it was really important to be closely monitored. However there 
were some concerns over the length of waiting time also on the amount of blood drawn 
for tests (they felt it was too much). They had concerns on randomization and false 
positivity as mentioned earlier they were not able to fully understand these terms even 
when explained in vernacular language. This was in line with the study by McGrath et 
al., (2001) on knowledge about vaccine trials where it was noted that most people were 
not familiar with the terms used in HVT for example randomization and placebo as they 
were difficult to understand when explained. Furthermore none of the participants had 
any serious side effect from vaccination apart from a slight pain at the site of the 
injection. Some had mild headache or fever which did not last longer than a few hours. 
These findings are congruent to the findings from a study conducted in Thailand where it 
was found that most participants experienced only minor side effects from vaccination 
(Pitisuttithum et al., 2006). This showed that the vaccine was safe and tolerable to most 
participants and could be used in future vaccine trials as examples to inform potential 
volunteers.  These findings imply to the need of improved package for educational 
seminar and the researchers should look for languages which are understandable to most 
people. Alternatively use of examples that are familiar to the research community to 
make sure that at the end they make an informed decision about participating in trials. In 
Mbeya community most people are very sensitive with blood related issue, they believe 
that blood is something which should not be taken by a person you don’t know, it is 
believed that one can harm another person (superstition) by using blood products. 
Therefore in these kinds of studies where large amount of blood are drawn for study 
purposes proper and detailed explanations are needed before enrolling participants.  
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Experiences at home and reaction of significant others 
The study revealed that respondents had varied experiences with community members. 
Some reported having nasty experiences with their spouses, friends and neighbors due to 
rumours connected to the vaccine trial. Similar findings were reported on the study by 
Sahay and colleagues (2004), where it was noted HVT participants experienced peers and 
family pressure also discrimination due to volunteering. People in the community 
believed that the participants were being injected with an active HIV virus and they were 
going to encounter a real infection which was made worse by the fact that participants 
may test positive in serological tests. These results are in line with the findings of the 
study conducted by Lesch and others (2006). It was pointed out that testing positive due 
to vaccine was an issue to most people as it was directly linked to real infection. The 
respondents reported that people who did not know the details (did not attend educational 
seminars) about the trial were the ones who were spreading wrong information in the 
community and thus increasing the negative attitude of people towards the trial and the 
participants. The respondents suggested we educate the whole community instead of 
educating only study participants.  
 The study showed that almost all female participants who were married or living with 
partners had to ask permission from their husbands to participate in the trial otherwise it 
may bring serious trouble at home. While there were male participants who took part in 
the study without wife’s permission, this implies to gender power issue with regard to 
cultural influences over women’s ability to make decision. This finding is consistence 
with the study by Woodsong (2004) on the use of topical microbicides where by it was 
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noted that based on socioeconomic status and cultural norms in African countries are 
likely to influence decision of women in using microbicides. It was also pointed out that 
men think that women should not use microbicides without informing them and receive 
approval (Woodsong, 2004). In another study conducted in Ghana by Tanner (2008) it 
was noted that relationship dynamics, power and gender roles had a great impact in the 
acceptability of microbicides use in women for HIV prevention. This qualitative study 
showed that great understanding and trust was needed among couples in Mbeya for one 
to continue in the trial as discouragements and de-motivators were many around the 
community. It also became evident that in couples where both partners participated in the 
study there were no problems and they supported each other in dealing with roumors and 
misconception. 
Elsewhere in the community it was said that the research centre was benefiting by selling 
participants’ blood to America while the participants were paid little money as 
compensation. These kinds of rumors had a big impact in terms of the recruitment as well 
as retention of participants in trials. However participants who had participated in other 
trials at MMRP had more knowledge on the trial procedure and had more trust to the 
research centre which enabled them to deal with pressure from other people (families, 
friends, neighbors). These kinds of rumors need to be well addressed in communities. 
 
HIV status, discordance and seroconversion during trial 
The study revealed that respondents were either not aware or they did not believe that one 
partner could be infected while the other was not (Serodiscordance). Some participants 
were denying their results based on their partners’ status or a wife having a HIV free 
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baby, this shows that more education is needed in communities. One respondent blamed 
the vaccine for causing HIV infection even after being unblinded and finding out that 
they were in the placebo group. However the study team and community advisory board 
investigated his sexual behaviors and he was found to have a high risk as he was having 
multiple sexual partners.  On the other hand respondents felt that they acquired HIV 
because they were at risk in one way or another. It also became evident from this study 
that acceptance in status change was related to partner's behaviors. It was noted that 
respondents did not struggle much in accepting their new status when their spouses had 
risky behaviors and they admitted having no grudges over them and it helped them to live 
with the problem (HIV). This is in line with the study by Pretorius and colleagues (2005) 
where it was noted that coming to terms with the disease was related to letting go of the 
anger/hate towards those thought to have infected them.  
 
Challenges to participation  
It became evident that respondents were aware that HIV is a problem, they perceived the 
risk to HIV for themselves and their generation and they felt that something has to be 
done to fight the disease. However they were faced by some challenges because of 
lacking adequate information on their safety. Most of the fears are already mentioned in 
the previous topics.  Furthermore the study revealed that respondents faced challenges in 
terms of time spent at the clinic (too long), the scheduled time for clinic visits as morning 
hours was the time best suited for income generating activities and studies. For instance 
for students it was found that some had to miss their sessions to attend study visits, this 
has an implication in involving students and adolescents in this kind of studies as most of 
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them are under 18 and still in school but they are already sexually active (Villafana et al., 
2006). The study on adolescents in HIV vaccine trials in Botswana showed that 1 in 
every 4 girls aged between 15-19 years were already infected with HIV and thus it is 
important to include youths in vaccine trials although is challenging due to legal 
implications, ethics allows participation at the age of 18 years and above (Villafana et al., 
2006). Transport was a reported challenge for the participants living far from the clinic. 
Problems in coping with rumours and stigma attached to participation by the community 
members was the most frequently mentioned challenge by respondents. This is congruent 
with findings in the study by Hollander (2008) where it was pointed out that one in every 
five volunteers in HIV vaccine efficacy trials experienced at least one negative social 
impact. It was further noted that 14% reported negative experiences and difficulties in 
interpersonal relationships i.e. negative reactions from partners, family, relatives and 
friends. Also these findings are supported by findings from a study conducted on 
vaccination against Human Pappiloma virus in Twente, by Van der Berg and Westerman, 
(2010) which pointed out that reasons for people not participating in the vaccination 
programme were perceived as dangers of the vaccine, also risk for side effects of the 
vaccine.  
Challenges to the researcher 
Although the study managed to explore and explain HVT participant’s expectation, 
experiences and challenges encountered during their participation in the trial. The 
research experienced some challenges during data collection and analysis. One of the 
challenges was to interview participants who had dropped out of the study and were 
unable to come at the clinic for interviews. For instance in one case the interview had to 
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be conducted at the respondent’s office after exhaustive efforts to reach her. It was also 
emotionally challenging to ask the questions about HIV status especially to participants 
who seroconverted during the study as this was attributed to study induced 
seroconversion. The researcher’s role in the trial and now as a researcher in this interview 
was therefore difficult especially in cases where participants mentioned that they 
seroconverted.  
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CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS 
The study has contributed to the understanding of HVT participant’s experiences and 
challenges encountered during participating in the trial. The findings in this study are 
important to the research team plans for future vaccine trials. Areas of concerns were 
identified which needs to be addressed by the research team conducting vaccine trials at 
MMRP especially capacitating the research community with all the necessary 
information before enrollment of volunteers. The elicited information will be used in 
improving the educational package and other aspects of the study based on the 
experiences of the people who took part in the trial. 
In this study it becomes evident that more and detailed information about the trial 
procedures and outcomes are needed during the educational and information seminars to 
deal with volunteers’ worries and concerns with regard to their safety. Therefore we 
recommend improving the package of information seminars with additional information, 
explanations and an emphasis on aspects which are of concern to the volunteers, for 
instance, information on the nature of the candidate vaccine, vaccine induced positivity, 
randomization and placebo.  
 
The study also revealed that participants experienced difficulties in the community due to 
rumours and misconceptions, as the people in the community are not well educated about 
the vaccine trials, therefore we recommend a continuous education program by the 
research centre to all communities where HVT is taking place, not only to volunteers in 
the trial, to help the communities understand the research and thus minimize rumors and 
misconceptions.  In addition we recommend the use of media like television and radio 
 
 
 
 
 57
programmes for community education as it was noted that when people heard something 
via the media, they believed that the authorities had approved it. 
 
The study found that there were serious family problems among couples where one was a 
HVT participant and the partner was not, due to misconceptions regarding the vaccine on 
trial. We recommend that the recruitment team should invite married couples or living 
together volunteers to a special session where, they have an opportunity to learn and 
make an informed decision together.  
 
In addition the possibilities of discordant results in couples should be well explained by 
nurse counselors during HIV counseling sessions, as the study showed a lack of 
knowledge on this. If possible, voluntary counseling and testing should be done to both 
partners, even if one of them would not be participating in the trial. 
 
The timing of visits to the clinic (morning hours and week days) was bringing some 
inconvenience to some participants like students, employees and other participants with 
busy daily schedules, therefore we recommend the research team organize some 
clinics/visits on weekends for participants who cannot make it on weekdays or organize 
for late evening clinics to accommodate the volunteers who are employed and the team 
should minimize the waiting time by scheduling a smaller or manageable number of 
participants per day. 
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Opinions and experiences elicited with regard to rumors and misconception about HVT 
in the community was only from the people participated in the study, it would be nice to 
conduct further studies to the community members surrounding the research centre for 
more understanding of issues related to participation in vaccine trials in the Mbeya 
community. 
 
The amount paid (10 USD) for compensation was found to be small compared to the time 
spent at the clinic and other inconveniences. Therefore we recommend a rise in 
compensation, not necessarily in cash; it could be food, vouchers.  
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APPENDIX 1: GUIDELINE OF THE IN-DEPTH INTERVIEW 
 
Introduction of the interviewer and the aim of interview 
Ask for permission to record the interview 
Note the time of starting the interview. 
Questions 
1. How did you know about HVT study? 
2. What motivated you into participating and what were you worries or fears 
3. What was your experience as a participant at the clinic? 
4. What was the experience as a participant at home, what did the people close to 
you feel or say regarding your participation in the trial? 
5. Were you free to tell the people at home that you are participating in the study? 
      Ask for reasons for what ever the answer the respondent gives. 
6. What was your experience with vaccination shots i.e. the first shot? 
and what about the other shots. 
7. What do you think about vaccine induced positivity?(The false positive) 
8. Would you like to discuss with me about your current HIV status. If yes then tell 
me how you feel about your status. 
9. Would you please tell me what you did appreciate in the trial what do you think 
needs improvement? 
Thank you so much for your time and cooperation, do you have any question before we 
close the interview? 
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APPENDIX 2: THEMES AND CODES 
A. Entering the study  
o Invitation and educational seminars 
o Challenges, experiences and expectations upon joining the trial  
B. Expectation and Motivation to participation. 
o Motivation to participate in HVT 
o Concerns/Worries to participate in HVT 
o Permission from partners/spouse 
C. Personal experiences at the clinic 
o Appointments/schedules and procedures 
o Trial procedures (Vaccination, Randomization, vaccine induced positivity) 
D. Personal experiences at home (in the community) 
o Spouses, family members, neighbors, workmates and friends (what did they 
feel, say, react) 
o Free to tell others about their participation 
o Misconception and rumors 
E. HIV status, discordance and seroconversion during the trial  
o Feelings on their current status 
o Experiences and challenges of those who seroconvert 
F. Challenges to participation and being in the study to the end 
o Perceived threat  
o Perceived benefits 
o Sustainability issues/Withdraw from the study 
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G. Participant’s opinion of the trial in general  
o What went well? - Strength 
o What needs improvement?- weakness 
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APPENDIX 3: PARTICIPANT INFORMATION SHEET (English) 
 
Date: ………………………….. 
Dear participant 
Thank you for agreeing to listen/read to information package concerning this study.  
What follows is an explanation of the study, purpose and process of the interview.  The 
study is for mini –thesis being conducted as a partial fulfillment for Masters Course in 
Public Health at the University of Western Cape.  You are free to ask me any question or 
clarification regarding this study. My contacts and those of my supervisors are written at 
the end of this sheet. 
 
Title of study 
Expectations and Experiences of HIV vaccine trial participants at the Mbeya Medical 
Research Programme in Mbeya, Tanzania 2006-2007. 
 
The Purpose of the study 
This study seeks to explore expectation and experiences of participants during the HIV 
vaccine trial at the clinic as well as in their families/community. With intention to 
improve recruitment and participation in future HVT by improving educational seminar 
package using experience and information received from volunteers who participated in 
the HIV vaccine trial before. 
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Description of Study 
The study will need you to undergo an in-depth interview of about 40-60 minutes at the 
clinic after finishing your routine scheduled activities. The interview will be audio 
recorded with your permission. The question will focus on your experiences as a HIV 
vaccine trial participant at MMRP.  
Anonymity of respondents (Confidentiality) 
At all times, I will keep the source of the information confidential and refer to you or 
your words by a nickname which I would like you to choose before the interview starts. I 
shall keep any other records of your participation locked away at all times, and destroy 
them after the study has been completed. The contents will be used for the purposes 
referred to above, but may be used for published or unpublished research at a later stage.   
 
Voluntary participation and withdraw 
Participation in this study entirely voluntary, you are free to withdraw at any point of 
interview if you decide to do so. The interview may touch on issues which could be 
sensitive to you in one way or another if there is anything that you would prefer not to 
discuss, please feel free to say so.  I will not be offended and there will be no negative 
consequences if you would prefer not to answer any question.  I would appreciate your 
guidance should I ask anything which you see as intrusive. 
 
Benefits and costs 
There may not be any direct benefits for you in taking part in this study, however the 
information received from the volunteers will help the Mbeya Medical Research team to 
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improve recruitment and retention of study participants in future studies and any success 
from these vaccine studies my benefit  your future generation. There no cost for 
participation in this study apart from the extra time you will spend at the clinic after 
finishing your routine activities. 
 
Informed consent 
If you understood my explanation and you are willing to participate in this study, I will 
request you to sign an informed consent form before I proceed with the interview. The 
form is attached to this information sheet you may review the form and decide whether 
you want to participate or not. 
 
Questions 
Should you have any further question about this study please contact me at 
Name: Erica Sanga 
UWC student no: 2706872 
Tel:  +255 25 2503364, Fax +255 25 2503134 and cell phone: + 255 762 577041 
E-mail:ericass80@hotmail.com or esanga@mmrp.org 
Institution: Mbeya Medical Research Programme (MMRP) 
 
I am accountable to Dr Leonard Maboko who is the principle investigator of the vaccine 
trial study and the Managing Director of MMRP, contactable at phone number + 255 25 
2503364 or Fax: 025 2503134 and by e-mail lmaboko@mmrp.org 
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APPENDIX 4: PARTICIPANT INFORMATION SHEET (Swahili) 
UKURASA WA MAELEZO KWA MSHIRIKI 
Tarehe: ………………………….. 
Ndugu Mshiriki 
Asante kwa kukubali kusilikiza/kusoma maelezo kuhusu utafiti huu.  Kifuatacho ni 
maelezo ya kina juu ya utafiti, malengo na taratibu za mahojiano.  Utafiti ni kwa ajili ya 
tasinifu ndogo, inayoanywa kama sehemu ya kukamilisha kozi ya shahada ya uzamili wa 
afya ya jamii katika chuo kikuu cha Western Cape kilichopo Afrika ya kusini. Una uhuru 
wa kuuliza swali lolote au ufafanuzi kuhusiana na utafiti huu. Maelezo juu ya jinsi ya 
kunifikia na pia wakuu wangu yameandikwa mwishoni mwa hii karatasi. 
Jina la utafiti 
Matarajio na uzoefu wa washiriki wa majaribio ya chanjo ya virusi vya ukimwi katika 
program ya  
utafiti wa tiba za binadamu mkoani Mbeya,Tanzania 2006-2007.  
 
Madhumuni ya utafiti 
Utafit huu unatafuta  kugundua matarajio na uzoefu wa washiriki wa majaribio ya chanjo 
ya virusi vya ukimwi katika maeneo ya kliniki na pia majumbani, katika familia zao na 
jamii kwa ujumla. 
 Ukiwa na lengo la kuboresha upatikanaji wa washiriki wa majaribio ya siku sijazo kwa 
kuboresha kifurushi cha semina elimishi kutegemeana na habari tutakazipata toka kwa 
washiriki waliowahi kushiriki katika majaribio haya hapo nyuma. 
Maelezo ya utafiti 
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Utafiti utakuhitaji ufanye mahojiano ya kina kwa takribani dakika 40-60 katika kliniki 
baada ya kumaliza taratibu zako zote za kawaida. Mahojiano yatarekodiwa iwapo 
utaruhusu. Maswali yatalenga kujua uzoefu wako kama mshiriki wa majaribio ya chanjo 
ya virusi vya ukimwi hapa  
MMRP. 
Usiri wa mshiriki na taarifa zake 
Wakati wote nitatunza chanzo cha taarifa zangu kwa usiri na nitakutambua kwa kutumia 
jina bandia ambalo utalichagua mwenyewe kabla ya kuanza mahojiano. Nitatunza taarifa 
nyingine zozote za ushiriki wako zikiwa zimefungiwa wakati wote na zitaharibiwa baada 
ya utafiti kwisha kabisa. Taarifa ulizotoa zitatumika kwa madhumuni yaliyotajwa hapo 
juu lakini pia yaweza kutumika kwa chapisho kataka hatua za baadaye.  
Hiari ya kushiriki au kujitoa 
Ushiriki wako katika utafiti ni wa hiari kabisa, uko huru kujitoa  wakati wowote wa 
mahojiano iwapo utaamua kufanya hivyo. Usahili au mahojiano yanaweza kugusa 
mambo ambayo ni nyeti kwako kwa njia moja au nyingine, iwapo kuna chochote 
ambacho hutapenda tuzungumzie, tafadhali kuwa huru kusema. Sitaudhika na 
hakutakuwa na shida/ubaya wowote iwapo utaamua kutojibu swali lolote. Nitashukuru 
kwa mwongozo wako endapo nitauliza swali ambalo unaliona ni kero. 
 
Faida na gharama 
Yawezekana kusiwe na faida ya moja kwa moja kwa wewe kushiriki katika utafiti huu, 
hata hivyo taarifa tutakazopata toka kwa washiriki zitasaidia timu ya watafiti kuboresha 
ushiriki na ukaaji wa washiriki katika tafiti zijazona pia mafanikio yatakayotokana na hizi 
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chanjo zinazojaribiwa yatasaidia katika kizazi kijacho. Hakuna gharama yoyote 
utakayotoa kwa kushiriki katika utafiti huu mbali na muda wa ziada utakaoutumia kliniki 
baada ya kumaliza utaratibu wako wa kawaida. 
 
Idhini ya ushiriki 
Iwapo umeyaelewa maelezo yangu na uko tayari kushiriki katika utafiti huu, nitakuomba 
uweke sahihi katika fomu hii ya kukubali kushiriki kabla ya kuendelea na mahojiano. 
Fomu imeambatanishwa na karatasi  ya maelezo unaweza kuipitiana uamue iwapo 
utapenda kushiriki au la. 
 
Maelezo/maswali zaidi 
Endapo utakuwa na maswali zaidi kuhusu utafiti huu tafadha wasiliana nami, Naitwa 
Erica Sanga 
 Namba ya uanafunzi UWC 2706872 
Simu: 255 25 2503364, Fax +255 25 2503134 na simu ya mkononi + 255 762 577041 
Barua pepe: ericass80@hotmail.com au esanga@mmrp.org 
Taasisi: Mbeya Medical Research Programme (MMRP) 
 
 Ninawajibika  kwa Dr Leonard Maboko  ambaye ndiye mtafiti mkuu wa majaribio ya 
chanjo ya virusi vya ukimwi na pia mkurugenzi wa MMRP,  anapatikana kwa simu 
namba + 255 25 2503364 au Fax: 025 2503134  na  e-mail lmaboko@mmrp.org. 
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APPENDIX 5: PARTICIPANT INFORMED CONSENT FORM(ENGLISH) 
Title of the study 
Expectations and Experiences of HIV vaccine trial participants at the Mbeya Medical 
Research Programme in Mbeya, Tanzania 2006-2007. 
Thank you for agreeing to take part in this study.   As mentioned earlier your 
participation in this study is entirely voluntary. You may decide not to participate or 
withdrawals at any point of the interview without loosing any privilege or benefit you are 
entitled to. 
You may also choose not to answer particular question asked during the course of 
interview be free to say whenever you feel that I am being intrusive, I wont be offended. 
Information received in this interview will be strictly confidently. 
If you decide to participate in this study, I please need you to sign before we proceed with 
the interview. 
I ………………………………….. Agree to take part in this study. I have read and 
understood the participant information sheet or it has been read to me. I understand that 
participation is voluntary and I have the right to withdraw from interview and free not to 
answer any questions I do not want to answer in this interview.  Also I have been assured 
of confidentiality of the information I give and I had the opportunity of asking questions 
and they were answered to the level of my satisfaction. 
……………………………………  ………………………………... 
Participants signature       Date 
…………………………………   ………………………………... 
Witness name and signature if the participant is illiterate  Date 
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…………………………………………………… 
Researcher’s name 
……………………………………………   …………………………… 
Researcher’s signature      Date    
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APPENDIX 6 : PARTICIPANT INFORMED CONSENT-Swahili 
IDHINI YA MSHIRIKI KUSHIRIKI 
Jina la utafiti 
Matarajio na uzoefu wa washiriki wa majaribio ya chanjo ya virusi vya ukimwi katika 
program ya utafiti wa tiba za binadamu mkoani Mbeya,Tanzania 2006-2007.  
Nakushukuru kwa kukubali kushiriki katika utafiti huu, kama ilivyoelezwa hapo awali 
kushiriki kwako ni kwa hiari kabisa. Unaweza kuamua kutoshiriki au kujitoa katika hatua 
yoyote ya majadiliano bila kupoteza faida yoyote ambayo unatakiwa kuipata.Unaweza 
pia kuchagua kutojibu baadhi ya maswali yatakayoulizwa wakati wa mahojiano, kuwa 
huru kusema wakati wowote utakapoona nakuingilia sana, sitaudhika.Taarifa 
zitakazopatikana katika mahojiano haya zitakuwa siri kubwa, Iwapo unaamua kushiriki 
katika utafiti huu, tafadhali nitakuomba usaini kabla hatujaendelea na mahojiano. 
 
Mimi………………………….. ..............................Nakubali kushiriki katika utafiti huu.  
Nimesoma/nimesomewa na kuelewa karatasi ya maelezo. Naelewa kwamba ushiriki 
wangu ni wa hiari na nina haki ya kujitoa kwenye mahojiano na nina uhuru wa kutojibu 
swali lolote nisilopenda kulijibu katika mahojiano haya. Pia nimehakikishiwa usiri wa 
taarifa nitakazotoa na nilipata  nafasi ya kuuliza maswali niliyokuwa nayo ambayo 
yalijibiwa kwa kiasi nilichoridhika. 
 
…………………………………………  ………………………………... 
Sahihi ya mshiriki       Tarehe 
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……………………………               ………………………………... 
Jina la shahidi na sahihi iwapo mshiriki hajui kusoma/kuandika Tarehe 
 
……………………......... 
Jina la mtafiti 
……………………………………   …………………………… 
Sahihi ya mtafiti       Tarehe  
 
 
 
 
